Fukuda M N, Gaetani G F, Izzo P, Scartezzini P, Dell A
La Jolla Cancer Research Foundation, California 92037.
Br J Haematol. 1992 Dec;82(4):745-52. doi: 10.1111/j.1365-2141.1992.tb06953.x.
Congenital dyserythropoietic anaemia type II, or HEMPAS (hereditary erythroblastic multinuclearity with positive acidified serum lysis test) is a genetic disease caused by membrane disorganization of erythroid cells. The primary defect of this disease lies in the gene encoding enzyme(s) which is responsible for the biosynthesis of Asn-linked oligosaccharides chains of glycoproteins (Fukuda et al, 1990). In order to know whether this gene defect affects the glycosylation in the cells other than the erythroid cells, the carbohydrate structures of the transferrin isolated from the sera of HEMPAS patients were analysed. Fast atom bombardment mass spectrometry analysis showed the presence of high mannose type and hybrid type oligosaccharides in the HEMPAS transferrin which is in contrast to the complex-type oligosaccharides found in the normal transferrin. The results strongly suggest that biosynthesis of Asn-linked oligosaccharide chains in HEMPAS hepatocytes is disturbed. As a result, the serum glycoproteins with incompletely processed carbohydrates are circulating in the plasma in HEMPAS patients, but they must have been absorbed by the cells in the liver and the reticuloendothelial cells. Upon intravenous infusion into rats, as much as 30% of the HEMPAS transferrin was cleared from the plasma circulation. The majority of the HEMPAS transferrins was taken up by the liver, and transferrin was distributed both in the hepatocytes and the Kupffer cells. The presence of enormous amounts of aberrantly glycosylated serum glycoproteins may lead to the liver cirrhosis and secondary tissue siderosis seen in HEMPAS patients.
II型先天性红细胞生成异常性贫血,即HEMPAS(遗传性红细胞多核伴酸化血清溶血试验阳性),是一种由红系细胞膜结构紊乱引起的遗传性疾病。该疾病的主要缺陷在于编码负责糖蛋白N - 糖链生物合成的酶的基因(Fukuda等人,1990年)。为了了解这种基因缺陷是否会影响除红系细胞以外的其他细胞中的糖基化作用,对从HEMPAS患者血清中分离出的转铁蛋白的碳水化合物结构进行了分析。快原子轰击质谱分析表明,HEMPAS转铁蛋白中存在高甘露糖型和杂合型寡糖,这与正常转铁蛋白中发现的复合型寡糖形成对比。结果强烈表明,HEMPAS肝细胞中N - 糖链的生物合成受到干扰。因此,碳水化合物加工不完全的血清糖蛋白在HEMPAS患者的血浆中循环,但它们必定已被肝脏细胞和网状内皮细胞吸收。将HEMPAS转铁蛋白静脉注射到大鼠体内后,高达30%的转铁蛋白从血液循环中清除。大部分HEMPAS转铁蛋白被肝脏摄取,并且转铁蛋白分布在肝细胞和库普弗细胞中。大量异常糖基化的血清糖蛋白的存在可能导致HEMPAS患者出现肝硬化和继发性组织铁沉积症。